Gilead Sciences Provides Update on Access Strategy for Lenacapavir for HIV Prevention

Gilead Sciences is a leading biopharmaceutical company committed to advancing medical research and developing innovative treatments for a range of therapeutic areas, including virology, HIV, viral hepatitis, COVID-19, oncology, and inflammation. With a strong focus on research and development, Gilead strives to improve patient outcomes and advance medical science.

One of the key pillars of Gilead’s research initiatives is its Research Funding Programs, which aim to support external-sponsored research in virology, oncology, and inflammation. Through these programs, Gilead provides opportunities for researchers to explore new treatment approaches and advance scientific understanding in these areas. Additionally, Gilead supports community-based participatory research to engage with local communities and address healthcare disparities.

In addition to supporting research, Gilead is dedicated to ensuring patient safety and medication access. The company has robust systems in place to prevent counterfeit medicines and ensure consumer product safety. Patients can also report adverse events related to Gilead medications, and the company provides resources for U.S. patient access and managed access programs.

Gilead also takes its corporate responsibility seriously, with a focus on environmental, social, and governance (ESG) performance. The company is committed to sustainability, with a particular focus on health equity. Through initiatives like Giving@Gilead, the company supports programs that aim to address healthcare disparities and improve access to healthcare for underserved communities.

One such initiative is the COMPASS Initiative, which focuses on improving outcomes for people affected by HIV in the Southern United States. Through programs like RADIAN and HepConnect, Gilead aims to address healthcare disparities and promote health equity across different communities. The company also supports initiatives like Zeroing In: Ending the HIV Epidemic, which aims to eliminate HIV transmission in the United States.

Gilead’s commitment to health equity is also reflected in its global initiatives, such as Access in Low- and Middle-Income Countries. Through partnerships and access strategies, Gilead works to ensure that patients in these regions have access to life-saving medications for conditions like invasive fungal infections. The company also supports inclusion and diversity through its employee resource groups like GAIN, GLOBE, and Women at Gilead.

Gilead’s dedication to medical education and advancing healthcare is evident in its diverse portfolio of medicines and ongoing research efforts. With a strong leadership team and a commitment to ethical business practices, Gilead continues to drive innovation in the field of biopharmaceuticals.